ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Celltrion secures EC approval for Remsima SC for five more indications
July 29, 2020Celltrion Healthcare has secured approval from the European Commission (EC) for the subcutaneous (SC) formulation of autoimmune disease drug Remsima (infliximab, CT-P13) for the treatment of five more indications. -
Celltrion's infliximab biosimilar to be tested for COVID-19
June 17, 2020Celltrion Healthcare has partnered with the University of Oxford and University Hospitals Birmingham to investigate the use of infliximab biosimilar CT-P13 as a treatment for COVID-19 symptoms. -
Celltrion Healthcare & Pfizer’s biosimilar shows positive results in Crohn’s disease study
May 08, 2019Celltrion Healthcare presented the primary outcome from its pivotal randomised controlled trial of CT-P13 (biosimilar infliximab) in Crohn’s disease.
Pharma Sources Insight January 2025
